Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | AKT1 | P31749 | 5/20 | 0.32 |
| ▸ | AKT2 | P31751 | 5/20 | 0.32 |
| ▸ | FABP4 | P15090 | 2/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL513508 | 0.86 | XIAP (0.36) | PTGS2AKT1AKT2FABP4 | |
| SCHEMBL514796 | 0.83 | AKT1 (0.45) | AKT1AKT2 | |
| SCHEMBL514797 | 0.83 | AKT1 (0.45) | AKT1AKT2 | |
| SCHEMBL14876784 | 0.83 | PTGS2 (0.35) | SYKPTGS2AKT1AKT2FABP4 | |
| SCHEMBL14876786 | 0.83 | PTGS2 (0.35) | SYKPTGS2AKT1AKT2FABP4 | |
| SCHEMBL513990 | 0.81 | XIAP (0.33) | PTGS2FABP4 | |
| SCHEMBL514149 | 0.79 | AKT1 (0.42) | AKT1AKT2 | |
| SCHEMBL514150 | 0.79 | AKT1 (0.42) | AKT1AKT2 | |
| SCHEMBL513102 | 0.79 | FABP4 (0.33) | FABP4 | |
| SCHEMBL514802 | 0.78 | PTGDR2 (0.35) | PTGS2AKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028918-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME | GLAXO WELLCOME MANUFACTURING PTE LTD. (SG) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028918-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SAME | PIK3CA, G6PC1, PIK3C2B | SYK 136/4885PTGS2 3234/4885AKT1 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.